Enable Accessibility Enable Accessibility

Directorate change

February 15, 2017

February 15, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) announces the following changes to Board committee membership, effective immediately:

Director

Appointment

Resignation

Dominic Blakemore

Remuneration Committee

N/A

Olivier Bohuon

Nomination & Governance Committee

Science & Technology Committee

Ian Clark

Remuneration Committee;
Science & Technology Committee

N/A

Sara Mathew

Nomination & Governance Committee

Remuneration Committee

Oliver Strawbridge
Senior Assistant Company Secretary

For further information please contact:

Investor Relations    
Ian Karp ikarp@shire.com +1 781 482 9018
Robert Coates rcoates@shire.com +44 1256 894874
Media    
Lisa Adler lisa.adler@shire.com +1 617 588 8607
Debbi Ford debbi.ford@shire.com +1 617 949 9083

NOTES TO EDITORS

About Shire

Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.

Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.

www.shire.com